Development of RApid Point-of-Care test Platforms for Infectious Diseases (RAPP-ID)


Project leader


Funding source

Innovative Medicines Initiative (IMI)


Project Details

Start date: 01/10/2012
End date: 01/04/2016
Funding: 6828438 EUR


Description

RAPP-ID (“Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital <2h, primary care <30min) detection of bacteria, mycobacteria, fungi, as well as viruses and host biomarkers by combining novel specific probes, novel methods of sample preparation, and demonstrated ultra-high sensitive detection methods. The platforms will also determine resistance to antimicrobial drugs. The research will focus on the biomarkers and pathogens involved in 1) Sepsis, 2) Lower Respiratory Tract Infections (LRTI), including Community-Acquired Pneumonia (CAP) and Ventilator-Associated Pneumonia (VAP), and 3) Tuberculosis (TB). Detection of bacteria, fungi and antibiotic resistance will mainly involve Nucleic Acid (NA) tests, whereas viral and host biomarker detection will mainly involve selective immunobinding with a probe or with a sensor surface. The diagnostic tests consist of in four functional modules: 1) sample collection and interfacing, 2) upconcentration and extraction, 3) signal and/or sample amplification, and 4) detection. RAPP-ID will integrate the minimum number of modules required for each disease/syndrome in a microfluidic cartridge, for which a breadboard reader with Graphical User Interface (GUI) provides the necessary optical/fluidic/electric/thermal interfaces. The integrated POCT will be validated on (spiked) reference samples and well characterised clinical samples and compared with the best reference standards and other standard available diagnostic tests.


Last updated on 2017-24-03 at 12:58